Abstract
Background: Viral infection is a common trigger of severe respiratory illnesses in early life and a risk factor for later asthma development. The mechanism leading to asthma could involve an aberrant airway immune response to viral infections, but this has rarely been studied in a human setting. Objectives: To investigate in situ virus-specific differences in upper airway immune mediator levels during viral episodes of respiratory illnesses and the association with later asthma. Methods: We included 493 episodes of acute respiratory illnesses in 277 children aged 0–3 years from the COPSAC2010 mother–child cohort. Levels of 18 different immune mediators were assessed in nasal epithelial lining fluid using high-sensitivity MesoScale Discovery kits and compared between children with and without viral PCR-identification in nasopharyngeal samples. Finally, we investigated whether the virus-specific immune response was associated with asthma by age 6 years. Results: Viral detection were associated with upregulation of several Type 1 and regulatory immune mediators, including IFN-ɣ, TNF-α, CCL4, CXCL10 and IL-10 and downregulation of Type 2 and Type 17 immune mediators, including CCL13, and CXCL8 (FDR <0.05). Children developing asthma had decreased levels of IL-10 (FDR <0.05) during viral episodes compared to children not developing asthma. Conclusion: We described the airway immune mediator profile during viral respiratory illnesses in early life and showed that children developing asthma by age 6 years have a reduced regulatory (IL-10) immune mediator level. This provides insight into the interplay between early-life viral infections, airway immunity and asthma development.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Allergy: European Journal of Allergy and Clinical Immunology |
Vol/bind | 79 |
Udgave nummer | 11 |
Sider (fra-til) | 2981-2992 |
Antal sider | 12 |
ISSN | 0105-4538 |
DOI | |
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:This study was funded by B\u00F8rnelungefonden \u2018The Children's Lung Foundation\u2019, Herlev and Gentofte Hospital's local foundation and Novo Nordisk Foundation (grant no: NNF18OC0031764). All funding received by COPSAC is listed on www.copsac.com . The Lundbeck Foundation (Grant no R16\u2010A1694); The Danish Ministry of Health (Grant no 903516); Danish Council for Strategic Research (Grant no 0603\u201000280B) and The Capital Region Research Foundation have provided core support to the COPSAC research center. Funding sources had no involvement writing or publication of this manuscript.
Publisher Copyright:
© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.